QHP Capital acquired Applied StemCell, Inc., a cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products.

ASC offers comprehensive and customized cell and gene CRO/CDMO solutions. Its platform of GMP-grade allogeneic induced pluripotent stem cells (iPSC) and its  TARGATT gene editing technology provide shorter manufacturing timelines, non-viral gene editing, and genomic stability and safety.

The reprogramming of somatic cells into iPSCs offers potential for cell therapy, primary research, disease modeling, and drug development. Human iPSCs can be generated in culture, expanded, and then used to manufacture clinical-grade cells of almost any cell type.

Future applications of iPSCs are expected to evolve beyond their use as life science tools, ranging from personalized drugs to regenerative cell therapies.

“Applied StemCell is dedicated to supporting the biopharmaceutical and research sectors in the pursuit of delivering transformative regenerative medicine treatments and cell therapy products,” said Ruby Chen-Tsai, CEO of Applied StemCell. “We are delighted to have the partnership with QHP Capital. ASC’s technology and capabilities combined with QHP’s strategic network and deep industry knowledge will help us accelerate our vision to enable the future cell